Athenex announces the promotion of Jeffrey M. Yordon

Athenex, announced  the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer (COO) for the company effective upon Board approval.  Previously Yordon was the president of the Athenex Pharmaceutical Division (APD), which was focused on commercializing all of Athenex’s products and intellectual property.

Yordon has had a long, distinguished career in the pharmaceutical industry with over 47 years of experience.  Previous to joining Athenex, he was the founder, chairman of the board and CEO of Sagent Pharmaceuticals which was recently sold to Nichi-Iko Pharmaceutical Company. Yordon was one of the founders of American Pharmaceutical Partners and served as President and COO of the company which was eventually purchased by Fresenius Kobi. Yordon also previously held senior management positions at YorPharm, LyphoMed, Faulding Pharmaceuticals and Gensia Laboratories.  "I am looking forward to working with the Athenex management team with a view to achieving key milestones and executing on our growth plan," stated Yordon.

About Athenex

Founded in 2003, Athenex, is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a Commercial Platform and an Global Supply Chain Platform. Our Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of our proprietary research and selection processes in the lab. Our current clinical pipeline is derived from two different platform technologies we call Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which we are able to facilitate oral absorption of traditional cytotoxics, which we believe may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. We believe the combination of these mechanisms of action provide a broader range of anti-cancer activity as compared to either mechanism of action alone.. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York ,Cranford, New Jersey , Houston, Texas , Chicago, Illinois , Hong Kong, S.A.R., China , Taipei Taiwan, China , and multiple locations in Chongqing , China.